A phase 1 clinical trial published in 2026 evaluated BBM-P002, an investigational gene therapy for Parkinson disease. Which ...
A target trial emulation pooling ACCORD-BP and SPRINT data found calcium channel blocker regimens reduced blood pressure variability without changing cardiovascular outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results